Compare HMY & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HMY | LNTH |
|---|---|---|
| Founded | 1950 | 1956 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 6.6B |
| IPO Year | 2002 | 2014 |
| Metric | HMY | LNTH |
|---|---|---|
| Price | $18.80 | $99.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $16.00 | ★ $87.00 |
| AVG Volume (30 Days) | ★ 3.7M | 922.1K |
| Earning Date | 02-04-2016 | 05-07-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.91 |
| Revenue | N/A | ★ $343,374,000.00 |
| Revenue This Year | $37.43 | N/A |
| Revenue Next Year | $27.44 | $14.19 |
| P/E Ratio | ★ $15.60 | $34.36 |
| Revenue Growth | N/A | ★ 3.62 |
| 52 Week Low | $13.03 | $49.67 |
| 52 Week High | $26.04 | $111.86 |
| Indicator | HMY | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 40.87 |
| Support Level | N/A | $99.92 |
| Resistance Level | N/A | $101.43 |
| Average True Range (ATR) | 0.00 | 0.44 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 0.93 |
Harmony Gold Mining Co Ltd is engaged in gold mining and related activities, including exploration, extraction, and processing. The group's primary product is gold bullion, produced at operations in South Africa and Papua New Guinea. Gold byproducts include uranium and silver. Strategic projects such as the Wafi-Golpu Project in the New Guinea Mobile Belt, the Eva Copper Project in the Mt Isa Inlier, Queensland, Australia, and the MAC Copper acquisition position the company as a gold-copper producer. The company operates across South Africa, Papua New Guinea, and Australia.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.